Evidence map›Paper›PMID 35164192›Full record

ArticleMolecules (Basel, Switzerland)2022

Coumarin-Resveratrol-Inspired Hybrids as Monoamine Oxidase B Inhibitors: 3-Phenylcoumarin

Marco Mellado, César González, Jaime Mella, Luis F Aguilar, Ismail Celik, Fernanda Borges, Eugenio Uriarte, Giovanna Delogu, Dolores Viña, Maria J Matos

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 5 countries.

Marco MelladoInstituto de Investigación y Postgrado, Facultad de Ciencias de la Salud, Universidad Central de Chile, Santiago 8330507, Chile.ORCID 0000-0001-9577-5180
César GonzálezDepartamento de Química, Universidad Técnica Federico Santa María, Valparaíso 2340000, Chile.ORCID 0000-0002-0830-8507
Jaime MellaInstituto de Química y Bioquímica, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2340000, Chile.ORCID 0000-0002-2434-8461
Luis F AguilarInstituto de Química, Facultad de Ciencias, Pontificia Universidad Católica de Valparaíso, Valparaíso 2340000, Chile.ORCID 0000-0002-6038-3475
Ismail CelikDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, 38000 Kayseri, Turkey.ORCID 0000-0002-8146-1663
Fernanda BorgesCIQUP, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, 4169-007 Porto, Portugal.ORCID 0000-0003-1050-2402
Eugenio UriarteDepartamento de Química Orgánica, Facultade de Farmacia, Universidade Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Giovanna DeloguDepartment of Life and Environmental Sciences, University of Cagliari, Monserrato, 09042 Cagliari, Italy.
Dolores ViñaChronic Diseases Pharmacology Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Maria J MatosCIQUP, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, 4169-007 Porto, Portugal.ORCID 0000-0002-3470-8299
Universidade de Santiago de Compostela · ESUniversidade do Porto · PTErciyes University · TRFederico Santa María Technical University · CLPontificia Universidad Católica de Valparaíso · CLUniversidad Central de Chile · CLUniversity of Cagliari · ITUniversity of Valparaíso · CL

Funding

Agencia Nacional de Investigación y Desarrollo Fondecyt Postdoctoral Grant 3180408Fundação para a Ciência e Tecnologia CEECIND/02423/2018 and UIDB/00081/2020Ministerio de Ciencia e Innovación PID2020-116076RJ-I00/AEI/10.13039/501100011033Vicerrectoría de Investigación y Estudios Avanzados of Pontificia Universidad Católica de Valparaíso VRIEA-PUCV 37.0/2017
6 · The paper itself

Abstract

Monoamine oxidases (MAOs) are attractive targets in drug design. The inhibition of one of the isoforms (A or B) is responsible for modulating the levels of different neurotransmitters in the central nervous system, as well as the production of reactive oxygen species. Molecules that act selectively on one of the MAO isoforms have been studied deeply, and coumarin has been described as a promising scaffold. In the current manuscript we describe a comparative study between 3-phenylcoumarin (

Indexed as

Catalytic DomainCoumarinsMolecular Docking SimulationMonoamine OxidaseMonoamine Oxidase InhibitorsResveratrolStyrenescoumarinCoumarinsMonoamine OxidaseMonoamine Oxidase InhibitorsResveratrolStyrenes3D-QSAR models3-phenylcoumarinmolecular dockingmolecular dynamicsmonoamine oxidase B inhibitorstrans-6-styrylcoumarintrans-resveratrol

Identifiers

PMID35164192
PMCPMC8838197
OpenAlexW4210463251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.